MDGL vs. BIIB, UTHR, INCY, NBIX, EXEL, BMRN, EXAS, HALO, RGEN, and IONS
Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.
Madrigal Pharmaceuticals vs.
Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Biogen received 1358 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 68.03% of users gave Madrigal Pharmaceuticals an outperform vote.
87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Biogen had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 10 mentions for Biogen and 8 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 1.20 beat Madrigal Pharmaceuticals' score of 1.13 indicating that Biogen is being referred to more favorably in the media.
Biogen presently has a consensus price target of $191.30, suggesting a potential upside of 41.19%. Madrigal Pharmaceuticals has a consensus price target of $416.33, suggesting a potential upside of 47.47%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Biogen.
Biogen has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.08, meaning that its stock price is 208% less volatile than the S&P 500.
Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Biogen has a net margin of 16.87% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.
Summary
Biogen beats Madrigal Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Madrigal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Madrigal Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MDGL) was last updated on 6/10/2025 by MarketBeat.com Staff
